September 2025 brought a mix of advances and setbacks in pulmonology, with new clinical trial readouts and regulatory updates highlighting the evolving landscape of respiratory care. Alongside these developments, new smoking cessation data further supported cytisinicline as a safe and effective tool, particularly for patients with COPD. Check out this September 2025 pulmonology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:1. The therapy was well-tolerated, and aTyr Pharma plans to discuss the findings with the FDA to determine a regulatory path forward. Mediation analysis suggested that active paternal smoking, offspring smoking, and childhood passive smoke exposure each partially contributed to these intergenerational effects.